Lonza | chemanager-online.com - Chemistry and Life Science

Dec. 09, 2019
Topics
Innovative Chemistry Between Mountains and Lakes
Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not ...
Dec. 06, 2019
Topics
Made in Switzerland – Exported Worldwide
The chemical, pharmaceutical and life sciences industries in Switzerland — organized in the Scienceindustries trade association — account for 45% of total exports with around 70,000 employees and are thus the undisputed ...
Nov. 13, 2019
News & Opinions
Lonza CEO Marc Funk Quits Unexpectedly
Marc Funk resigned as CEO of Lonza on Nov. 12, citing personal reasons, after only eight months at the helm of the Swiss CDMO. The news took most observers and investors by surprise, and the company’s share price gave up 4.5%.
Sep. 11, 2019
Topics
The Pharma CDMO Challenge
The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manufacturing to contract development and manufacturing ...
Sep. 11, 2019
Topics
Experts Statements: Christian Dowdeswell, Lonza
The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manufacturing to contract development and manufacturing ...
Sep. 10, 2019
Topics
Continuous Processing
Is it possible to learn from other industries or are we doomed to repeat the same mistakes in the pharma sector? Not long ago, I came across a Forbes article which described how streaming service provider Netflix proposed a partnership to ...
Sep. 05, 2019
News & Opinions
Lonza to Produce Biosimilar for Celltrion
Swiss fine chemicals producer Lonza has signed a contract manufacturing agreement with Korea-based biosimilars producer Celltrion to supply a drug substance for Remsima, a biosimilar that is approved by the European Medicines Agency (EMA) ...
Jul. 15, 2019
News & Opinions
Lonza Completes Tampa Expansion
Swiss fine chemicals producer and drug developer Lonza has completed a $15 million multi-phase expansion at its site in Tampa, Florida, USA, adding solid oral dose development and manufacturing capabilities. ...
Jul. 02, 2019
News & Opinions
Lonza to Acquire Swiss Facility from Novartis
Swiss fine chemicals producer and drug developer Lonza has signed a binding agreement to acquire a sterile drug product fill & finish plant from Novartis, the first such facility in its production network. In future, the company will ...
Jun. 04, 2019
News & Opinions
Lonza Splits Specialty Ingredients, Plans Job Cuts
Swiss fine chemicals company Lonza is carving out its specialty ingredients (LSI) segment under independent management, giving it increased control over operations and costs. LSI will, however, remain fully owned by Lonza. ...

12 3 4 5 6 7 8…

Register now!

The latest information directly via newsletter.

GIT Verlag